Language:

Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies

Nature (London), 2021-05, Vol.593 (7857), p.136-141 [Peer Reviewed Journal]

Copyright Nature Publishing Group May 6, 2021 ;ISSN: 0028-0836 ;EISSN: 1476-4687 ;DOI: 10.1038/s41586-021-03412-7 ;PMID: 33706364

Full text available

Citations Cited by

Actions
1. Add to My Research
2. Remove from My Research
3. E-mail
4. Print
5. Permalink
6. Citation
7. EasyBib
8. EndNote
9. RefWorks
10. Delicious
11. Export RIS
12. Export BibTeX

Title:
Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies
Author: Collier, Dami A ; De Marco, Anna ; Ferreira, Isabella A T M ; Meng, Bo ; Datir, Rawlings P ; Walls, Alexandra C ; Kemp, Steven A ; Bassi, Jessica ; Pinto, Dora ; Silacci-Fregni, Chiara ; Bianchi, Siro ; Tortorici, M Alejandra ; Bowen, John ; Culap, Katja ; Jaconi, Stefano ; Cameroni, Elisabetta ; Snell, Gyorgy ; Pizzuto, Matteo S ; Pellanda, Alessandra Franzetti ; Garzoni, Christian ; Riva, Agostino ; Elmer, Anne ; Kingston, Nathalie ; Graves, Barbara ; McCoy, Laura E ; Smith, Kenneth G C ; Bradley, John R ; Temperton, Nigel ; Ceron-Gutierrez, Lourdes ; Barcenas-Morales, Gabriela ; Harvey, William ; Virgin, Herbert W ; Lanzavecchia, Antonio ; Piccoli, Luca ; Doffinger, Rainer ; Wills, Mark ; Veesler, David ; Corti, Davide ; Gupta, Ravindra K
Subjects: Aged ; Aged, 80 and over ; Amino acid sequence ; Amino acids ; Angiotensin-Converting Enzyme 2 - metabolism ; Antibodies, Monoclonal - immunology ; Antibodies, Monoclonal - isolation & purification ; Antibodies, Neutralizing - immunology ; Antibodies, Neutralizing - isolation & purification ; Antibodies, Viral - immunology ; Antibodies, Viral - isolation & purification ; Binding ; Coronaviruses ; COVID-19 ; COVID-19 - immunology ; COVID-19 - metabolism ; COVID-19 - therapy ; COVID-19 - virology ; COVID-19 Serotherapy ; COVID-19 vaccines ; COVID-19 Vaccines - immunology ; Disease transmission ; Domains ; Female ; HEK293 Cells ; Humans ; Immune Evasion - genetics ; Immune Evasion - immunology ; Immune response ; Immunization ; Immunization, Passive ; Interferometry ; Male ; Middle Aged ; Models, Molecular ; Monoclonal antibodies ; mRNA ; mRNA Vaccines ; Mutation ; Neutralization ; Neutralization Tests ; Neutralizing ; Proteins ; Receptors ; SARS-CoV-2 - genetics ; SARS-CoV-2 - immunology ; Severe acute respiratory syndrome ; Severe acute respiratory syndrome coronavirus 2 ; Spike Glycoprotein, Coronavirus - chemistry ; Spike Glycoprotein, Coronavirus - genetics ; Spike Glycoprotein, Coronavirus - immunology ; Spike Glycoprotein, Coronavirus - metabolism ; Spike protein ; Substitutes ; Vaccination ; Vaccines ; Vaccines, Synthetic - administration & dosage ; Vaccines, Synthetic - immunology ; Viruses
Is Part Of: Nature (London), 2021-05, Vol.593 (7857), p.136-141
Description: Transmission of SARS-CoV-2 is uncontrolled in many parts of the world; control is compounded in some areas by the higher transmission potential of the B.1.1.7 variant , which has now been reported in 94 countries. It is unclear whether the response of the virus to vaccines against SARS-CoV-2 on the basis of the prototypic strain will be affected by the mutations found in B.1.1.7. Here we assess the immune responses of individuals after vaccination with the mRNA-based vaccine BNT162b2 . We measured neutralizing antibody responses after the first and second immunizations using pseudoviruses that expressed the wild-type spike protein or a mutated spike protein that contained the eight amino acid changes found in the B.1.1.7 variant. The sera from individuals who received the vaccine exhibited a broad range of neutralizing titres against the wild-type pseudoviruses that were modestly reduced against the B.1.1.7 variant. This reduction was also evident in sera from some patients who had recovered from COVID-19. Decreased neutralization of the B.1.1.7 variant was also observed for monoclonal antibodies that target the N-terminal domain (9 out of 10) and the receptor-binding motif (5 out of 31), but not for monoclonal antibodies that recognize the receptor-binding domain that bind outside the receptor-binding motif. Introduction of the mutation that encodes the E484K substitution in the B.1.1.7 background to reflect a newly emerged variant of concern (VOC 202102/02) led to a more-substantial loss of neutralizing activity by vaccine-elicited antibodies and monoclonal antibodies (19 out of 31) compared with the loss of neutralizing activity conferred by the mutations in B.1.1.7 alone. The emergence of the E484K substitution in a B.1.1.7 background represents a threat to the efficacy of the BNT162b2 vaccine.
Publisher: England: Nature Publishing Group
Language: English
Identifier: ISSN: 0028-0836
EISSN: 1476-4687
DOI: 10.1038/s41586-021-03412-7
PMID: 33706364
Source: ProQuest One Psychology
MEDLINE
ProQuest Central

Back to results list


INSPIRE LIBRARY - TON DUC THANG UNIVERSITY	(84-028) 37 755 057	Feedback
19 Nguyen Huu Tho St. Dist.7, HCM	thuvien@tdtu.edu.vn	Feedback

Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies

Copyright Nature Publishing Group May 6, 2021 ;ISSN: 0028-0836 ;EISSN: 1476-4687 ;DOI: 10.1038/s41586-021-03412-7 ;PMID: 33706364

Searching Remote Databases, Please Wait